December 05, 2025

LuPSMA-617 Plus Hormone Therapy Improves Radiographic Progression–Free Survival in Metastatic Hormone-Naive Prostate Cancer

The addition of lutetium-177–labeled PSMA-617 (vipivotide tetraxetan; LuPSMA-617), a targeted radionuclide therapy, to standard-of-care androgen-deprivation therapy and an androgen receptor pathway in...

The ASCO Post

December 05, 2025

Primary Analysis Shows Survival Benefit With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer

The addition of bemarituzumab, a first-in-class anti-FGFR2b antibody, to mFOLFOX6 chemotherapy significantly improved overall survival in patients with FGFR2b-overexpressing (≥ 10% tumor cell staining...

The ASCO Post

December 05, 2025

Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC

In the phase III HARMONi-6 trial, conducted in China, the bispecific antibody ivonescimab, given with chemotherapy, improved progression-free survival by 4.2 months over the PD-1 inhibitor tislelizuma...

The ASCO Post

December 02, 2025

Preliminary Activity of LuPSMA-I&T Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis

In an interim analysis of an Australian single-center phase I/II trial (AlphaBet) reported in The Lancet Oncology, Kostos et al found that the combination of lutetium-177–labeled PSMA-I&T (LuPSMA-...

The ASCO Post

November 25, 2025

Adjuvant Use of Atezolizumab Plus Chemotherapy in DNA Mismatch Repair–Deficient Colon Cancer

For the adjuvant treatment of stage III colon cancer with DNA mismatch repair–deficient (dMMR) tumors, the addition of the checkpoint inhibitor atezolizumab to standard chemotherapy significantly impr...

The ASCO Post

November 25, 2025

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma

On November 6, 2025, the U.S. Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for adults with high-risk smoldering multiple myeloma.

The ASCO Post

November 25, 2025

Long-Term Survival With Stereotactic Ablative Radiotherapy vs Surgery for Early-Stage NSCLC

With 10 years of follow-up, no significant difference in survival rates was reported between patients who were treated with stereotactic ablative radiotherapy (SABR) or video-assisted thoracoscopic su...

The ASCO Post

November 25, 2025

Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer

The addition of the PD-1 inhibitor pembrolizumab to weekly paclitaxel, with or without the VEGFA-targeted bevacizumab, significantly improved progression-free survival and overall survival in patients...

The ASCO Post

November 24, 2025

Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas

The addition of the PD-L1–targeting monoclonal antibody durvalumab to conventional perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a statistical...

The ASCO Post